Literature DB >> 27084911

Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus.

Alexandra Legge1, Steve Doucette1, John G Hanly2.   

Abstract

OBJECTIVE: To describe organ damage accrual, predictors of damage progression, and effect on health-related quality of life (HRQOL) in patients with systemic lupus erythematosus (SLE).
METHODS: A longitudinal database of patients who met the American College of Rheumatology (ACR) classification criteria for SLE was used. Annual assessments included the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) and the Medical Outcomes Study Short Form-36 (SF-36). The prognostic significance of demographic, disease-related, and treatment-related factors on damage progression was examined using multivariable Cox regression. The effect of changes in SDI scores on HRQOL, measured using the SF-36 summary and subscale scores, was assessed using linear mixed-effects modeling.
RESULTS: There were 273 patients with SLE studied over a mean (SD) duration of followup of 7.3 (4.3) years. During followup, 126 (46.2%) had an increase in SDI scores. Patients with preexisting damage at baseline were more likely to have earlier damage progression (HR 2.09, 95% CI 1.44-3.01). Older age, ≥ 8 ACR classification criteria, immunosuppressive drugs, cigarette smoking, and higher mean serum C-reactive protein levels were associated with an earlier increase in SDI scores in multivariable analysis. In general, changes in SDI scores were associated with initial declines in SF-36 scores at the time that damage occurred, with subsequent change comparable to that seen in patients without damage progression.
CONCLUSION: This study identified multiple risk factors, some modifiable, associated with damage progression in patients with SLE. The negative effect on HRQOL emphasizes the need for treatment strategies to reduce the risk of organ damage over time.

Entities:  

Keywords:  DAMAGE; HEALTH-RELATED QUALITY OF LIFE; SYSTEMIC LUPUS ERYTHEMATOSUS

Mesh:

Year:  2016        PMID: 27084911     DOI: 10.3899/jrheum.150985

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study.

Authors:  Iñigo Rúa-Figueroa; Celia Erausquin; Celia Rua-Figueroa; Jesús González-Martín; Antonio Naranjo; Soledad Ojeda; Félix Francisco; Juan C Quevedo; Laura Cáceres; Ruben López; Martin Greco; Irene Altabás-González; Yanira Pérez; Francisco Rubiño; Carlos Rodríguez-Lozano
Journal:  Rheumatol Int       Date:  2019-11-27       Impact factor: 2.631

2.  Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus.

Authors:  Romy Kallas; Jessica Li; Michelle Petri
Journal:  Clin Rheumatol       Date:  2019-11-08       Impact factor: 2.980

3.  Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE.

Authors:  Lina Wirestam; Martina Frodlund; Helena Enocsson; Thomas Skogh; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus Sci Med       Date:  2017-07-28

4.  Prediction of chronic damage in systemic lupus erythematosus by using machine-learning models.

Authors:  Fulvia Ceccarelli; Marco Sciandrone; Carlo Perricone; Giulio Galvan; Francesco Morelli; Luis Nunes Vicente; Ilaria Leccese; Laura Massaro; Enrica Cipriano; Francesca Romana Spinelli; Cristiano Alessandri; Guido Valesini; Fabrizio Conti
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

5.  Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.

Authors:  Chiara Tani; Roberta Vagelli; Chiara Stagnaro; Linda Carli; Marta Mosca
Journal:  Lupus Sci Med       Date:  2018-02-27

6.  Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.

Authors:  N Groot; D Shaikhani; Y K O Teng; K de Leeuw; M Bijl; R J E M Dolhain; E Zirkzee; R Fritsch-Stork; I E M Bultink; S Kamphuis
Journal:  Arthritis Rheumatol       Date:  2019-02       Impact factor: 10.995

7.  Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI).

Authors:  Matteo Piga; Alberto Floris; Gerard Espinosa; Luísa Serpa Pinto; Nikolaos Kougkas; Andrea Lo Monaco; Giuseppe Lopalco; Ida Orlando; Vittorio Pirani; Ernestina Santos; George Bertsias; Luca Cantarini; Alberto Cauli; Ricard Cervera; João Correia; Marcello Govoni; Florenzo Iannone; Piergiorgio Neri; Ana Martins Silva; Carlos Vasconcelos; Monica Muntoni; Alessandro Mathieu
Journal:  RMD Open       Date:  2020-07

Review 8.  Treatment of Lupus Nephritis from Iranian Traditional Medicine and Modern Medicine Points of View: A Comparative Study.

Authors:  Yasaman Vahedi-Mazdabadi; Mina Saeedi
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-09       Impact factor: 2.629

9.  The effect of smoking on cumulative damage in systemic lupus erythematosus: An incident cohort study.

Authors:  Trevor McKown; Maria Schletzbaum; Rachna Unnithan; Xing Wang; Nnenna Ezeh; Christie M Bartels
Journal:  Lupus       Date:  2021-01-20       Impact factor: 2.911

10.  EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.

Authors:  Julius Lindblom; Alvaro Gomez; Alexander Borg; Sharzad Emamikia; Dimitris Ladakis; Joaquin Matilla; Martin Pehr; Flordelyn Cobar; Yvonne Enman; Emelie Heintz; Malin Regardt; Ioannis Parodis
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.